Related Experiment Video
Updated: Jun 26, 2025
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
13.2K
Optimizing BTK Inhibition in Waldenström Macroglobulinemia
Shayna Sarosiek1, Jorge J Castillo1
11Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Summary
Bruton tyrosine kinase (BTK) inhibitors are key for Waldenström macroglobulinemia (WM). A genomic approach can optimize patient selection for better responses and manage side effects of these important BTK therapies.
Area of Science:
- Oncology
- Hematology
- Pharmacogenomics
Background:
- Bruton tyrosine kinase (BTK) inhibitors are FDA-approved and a standard of care for Waldenström macroglobulinemia (WM).
- Optimizing BTK inhibitor therapy requires identifying patients likely to benefit and managing associated adverse effects.
Purpose of the Study:
- To propose a genomic-driven approach for selecting WM patients who will achieve optimal responses to BTK inhibitors.
- To provide practical strategies for managing adverse effects of BTK inhibitor therapy in WM patients.
Main Methods:
- Genomic analysis to identify predictive biomarkers for BTK inhibitor response.
- Review and synthesis of clinical strategies for managing BTK inhibitor-related adverse events.
Main Results:
- A genomic-driven approach can enhance patient selection for improved BTK inhibitor efficacy in WM.
- Established strategies for managing adverse effects include dose modification, switching BTK inhibitors, or discontinuation.
Conclusions:
- Genomic insights hold promise for personalizing BTK inhibitor treatment in WM.
- Effective management of adverse effects is crucial for sustained BTK inhibitor therapy in WM patients.
- Future research includes evaluating novel BTK inhibitors and degraders in ongoing clinical trials.
